Our progress is supported by renowned institutions: 

NASA_logo.svg.png
bristol_larger_logo.png
Imperial_logo.svg.png
ISS LOGO.png
Beth_Israel_Deaconess_Medical_Center_BID
harvard.png
NIAID.png
CDMRPlogo.png
queen_mary_university_of_london_logo_720

Developing first-in-class therapeutics 

Disease/Injury manipulates the ICE to enable its progression; reverting ICE changes makes it possible to develop treatment for every disease. 

MicroQuin focuses in-house efforts on Cancer, while progressing Anti-Virals and Neuro with the support of collaborators.  

Focusing on transforming cancer treatment for solid tumors

MicroQuin's orally available lead small molecule, SMQ-2174, exclusively induces rapid cancer death irrespective of the cancer type.

Images.jpg